Humira (Adalimumab)

Humira is a prescription medication that contains the active ingredient adalimumab, supplied as a subcutaneous injection. It is a biologic immunosuppressant classified as a tumor necrosis factor (TNF) inhibitor, marketed in the European Union for the treatment of several inflammatory and autoimmune conditions.

Humira is indicated for a range of chronic inflammatory diseases where modulation of the immune response is required.

- Rheumatoid arthritis in adults who have not responded adequately to conventional therapy. - Psoriatic arthritis to reduce joint pain and skin lesions. - Ankylosing spondylitis for improvement of spinal mobility. - Moderate to severe Crohn's disease and ulcerative colitis. - Plaque psoriasis when other systemic treatments are insufficient. - Hidradenitis suppurativa and non-infectious uveitis as adjunct therapy.

Adalimumab may cause a variety of adverse reactions, ranging from mild to severe. Patients should be aware of both common and serious potential effects.

Common: - Injection site pain, redness, or swelling. - Upper respiratory tract infections such as sinusitis or nasopharyngitis. - Headache and fatigue. - Nausea or mild gastrointestinal discomfort. - Mild rash or itching.

Serious: - Serious infections including tuberculosis, bacterial sepsis, or opportunistic fungal infections. - Reactivation of hepatitis B virus. - Development of malignancies such as lymphoma. - Neurological disorders including demyelinating disease. - Severe allergic reactions (anaphylaxis, serum sickness).

Before starting Humira, patients and clinicians should consider several safety factors.

- Screen for latent tuberculosis and hepatitis B; treat active infections before initiating therapy. - Evaluate for a history of malignancy, especially lymphoma or skin cancers. - Monitor for signs of infection throughout treatment. - Use caution in patients with congestive heart failure or demyelinating disorders. - Discuss pregnancy and breastfeeding plans, as safety data are limited. - Regular laboratory monitoring (CBC, liver enzymes) may be recommended. - Vaccinations should be up to date before treatment, avoiding live vaccines during therapy.

Humira can influence the activity of other medicines, and some combinations require special attention.

Avoid: - Live vaccines (e.g., yellow fever, BCG) because immunosuppression may increase infection risk. - Concurrent use with other biologic immunosuppressants (e.g., abatacept, rituximab) due to heightened infection risk.

Use with caution: - Systemic corticosteroids, as combined immunosuppression may raise infection susceptibility. - Methotrexate or azathioprine, which can augment immunosuppressive effects. - Antiviral agents for hepatitis B, requiring close monitoring of viral load. - Drugs that affect wound healing (e.g., NSAIDs) when surgery is planned. - Concomitant antibiotics, ensuring appropriate coverage for opportunistic pathogens.